Dihydroergotamine (DHE) - Current Role in the Management of Migraine

DHE has been approved in the US since 1943, and Europe since 1946, for the acute treatment of migraine. DHE has broad receptor effects unlike many of the receptor-specific drug classes developed and approved since starting with the triptans, CGRP targeting drugs, ditans and others in development. Intravenous (IV) DHE, usually administered with an antiemetic in a monitored specialty or inpatient settings, remains the favored approach for refractory migraine, status migrainosus, chronic migraine with medication overuse, and treatment refractory migraines. This narrative review examines the historical development, mechanisms, clinical evidence, delivery systems, safety considerations, and current therapeutic role of DHE in migraine management. The classic repeat-dose IV regimen, first reported in 1986, strongly influenced current infusion practice, although the original evidence was nonrandomized and preceded modern trial standards. The traditional nasal spray, approved in 1997 demonstrated variable superiority over placebo across four pivotal trials for headache relief. Recent nasal product approvals relied on pharmacokinetic (PK) bridging and long-term safety programs and were aimed, with the subcutaneous autoinjector, at facilitating DHE use as outpatient self-treatment, but their evidence bases differ substantially. Pulmonary inhalation products may generate PK profiles closer to IV DHE but remain investigational. DHE's main limitations are nausea, practical barriers to administration, and cardiovascular (CV) safety concerns - although emerging observational data suggest that carefully selected patients even with CV risk factors may tolerate monitored IV DHE placing it not as a routine first-line treatment for uncomplicated attacks, but as a valuable rescue and specialty-care option in the toolbox.